针对阿尔茨海默氏病途径的生物异构体修饰的最新进展
Akash Verma1, Digambar Kumar Waiker2, Prem Shanker Gupta1
1Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad 244001, U.P., India.
Bioorganic chemistry
|November 25, 2025
概括
生物异构主义提供了一种化学策略,用于增强药物特性,用于治疗阿尔茨海默氏症 (AD) 等脑疾病. 这种方法优化了分子特征,提高了药物的有效性和患者的治疗结果.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药物发现 药物发现 药物发现
背景情况:
- 药物开发是昂贵的,耗时的,并且面临着像帕金森病 (PD) 和阿尔茨海默病 (AD) 等大脑疾病的挑战.
- 目前针对PD和AD的治疗方法由于疾病的复杂性和血脑屏障 (BBB) 穿透性差,有效性有限.
- 优化候选药物的分子特性对于提高选择性,稳定性,药理动力学和BBB透性至关重要.
研究的目的:
- 在药物发现中审查最近的生物异构体替代策略.
- 要突出生物异质化如何优化分子性质以提高生物有效性.
- 专注于生物异构学在治疗阿尔茨海默病 (AD) 的应用.
主要方法:
- 对最近生物异构体替代方法的文献综述.
- 在药物设计中对分子性质优化的分析.
- 专注于针对AD的药物开发策略.
主要成果:
- 生物异构主义是修改药物分子的宝贵工具.
- 通过生物异构主义替代功能组可以改善药理动力学并降低毒性.
- 优化的分子特性提高了药物的有效性,特别是在中枢神经系统疾病中.
结论:
- 生物异构体替代是克服开发神经退行性疾病有效治疗的挑战的关键策略.
- 这种方法可以为改善大脑透和阿尔茨海默病治疗结果量身定制药物.
- 进一步应用生物异构学有望促进复杂神经疾病的药物发现.
相关概念视频
01:22Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K